These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 21836410)

  • 1. Age-related macular degeneration, anti-vascular endothelial growth factor agents, and short-term mortality: a postmarketing medication safety and surveillance study.
    French DD; Margo CE
    Retina; 2011 Jun; 31(6):1036-42. PubMed ID: 21836410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.
    Boyer DS; Heier JS; Brown DM; Francom SF; Ianchulev T; Rubio RG
    Ophthalmology; 2009 Sep; 116(9):1731-9. PubMed ID: 19643495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study.
    Fong DS; Custis P; Howes J; Hsu JW
    Ophthalmology; 2010 Feb; 117(2):298-302. PubMed ID: 19969368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab.
    Wehrli SJ; Tawse K; Levin MH; Zaidi A; Pistilli M; Brucker AJ
    Retina; 2012 Jul; 32(7):1295-301. PubMed ID: 22466465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis.
    Campbell RJ; Bell CM; Paterson JM; Bronskill SE; Moineddin R; Whitehead M; Gill SS
    Ophthalmology; 2012 Aug; 119(8):1604-8. PubMed ID: 22717458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration?
    Schaal S; Kaplan HJ; Tezel TH
    Ophthalmology; 2008 Dec; 115(12):2199-205. PubMed ID: 18930553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Introducing Anti-Vascular Endothelial Growth Factor Therapies for AMD Did Not Raise Risk of Myocardial Infarction, Stroke, and Death.
    Yashkin AP; Hahn P; Sloan FA
    Ophthalmology; 2016 Oct; 123(10):2225-31. PubMed ID: 27523614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.
    Landa G; Amde W; Doshi V; Ali A; McGevna L; Gentile RC; Muldoon TO; Walsh JB; Rosen RB
    Ophthalmologica; 2009; 223(6):370-5. PubMed ID: 19590252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effectivity and safety of bevacizumab intravitreal injections for exudative age-related macular degeneration treatment--6 months observations].
    Małgorzata F
    Klin Oczna; 2010; 112(7-9):213-6. PubMed ID: 21121123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements.
    Shah AR; Del Priore LV
    Br J Ophthalmol; 2009 Aug; 93(8):1027-32. PubMed ID: 19429594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
    Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
    Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
    Melamud A; Stinnett S; Fekrat S
    Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration.
    Lee SJ; Koh HJ
    Ophthalmology; 2011 Jan; 118(1):101-10. PubMed ID: 20678805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file.
    Brechner RJ; Rosenfeld PJ; Babish JD; Caplan S
    Am J Ophthalmol; 2011 May; 151(5):887-895.e1. PubMed ID: 21310390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bilateral intravitreal injection of antivascular endothelial growth factor therapy.
    Mahajan VB; Elkins KA; Russell SR; Boldt HC; Gehrs KM; Weingeist TA; Stone EM; Abràmoff MD; Liu D; Folk JC
    Retina; 2011 Jan; 31(1):31-5. PubMed ID: 21187731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration.
    Wickremasinghe SS; Michalova K; Gilhotra J; Guymer RH; Harper CA; Wong TY; Qureshi S
    Ophthalmology; 2008 Nov; 115(11):1911-5. PubMed ID: 18672291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population-based incidence of exudative age-related macular degeneration and ranibizumab treatment load.
    Geirsdottir A; Jonsson O; Thorisdottir S; Helgadottir G; Jonasson F; Stefansson E; Sigurdsson H
    Br J Ophthalmol; 2012 Mar; 96(3):444-7. PubMed ID: 21856691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of myocardial infarction, stroke, and death in patients with age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor therapy.
    Ng WY; Tan GS; Ong PG; Cheng CY; Cheung CY; Wong DW; Mathur R; Chow KY; Wong TY; Cheung GC
    Am J Ophthalmol; 2015 Mar; 159(3):557-64.e1. PubMed ID: 25497143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections.
    Hoang QV; Mendonca LS; Della Torre KE; Jung JJ; Tsuang AJ; Freund KB
    Ophthalmology; 2012 Feb; 119(2):321-6. PubMed ID: 22054994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.